Immunic to Participate in Industry and Investor Conferences in November

Rhea-AI Summary

Immunic (Nasdaq: IMUX) will participate in industry and investor conferences in November 2025. Company executives will attend BIO-Europe in Vienna on Nov 3–5, 2025 for partnering activities, with Daniel Vitt, Ph.D., Hella Kohlhof, Ph.D., and Jessica Breu representing the company.

Immunic executives will also host one-on-one meetings in London on Nov 19–20, 2025 in connection with the Jefferies Global Healthcare Conference—London; Daniel Vitt and Jason Tardio will attend. To schedule meetings, contact Jessica Breu via jessica.breu@imux.com or use the BIO-Europe partneringONE portal.

NEW YORK, Oct. 29, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in November:

• November 3-5: BIO-Europe. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, Hella Kohlhof, Ph.D., Chief Scientific Officer and Jessica Breu, Vice President Investor Relations and Communications, will participate in partnering activities at this conference in Vienna, Austria. To schedule a meeting, please use the BIO-Europe partneringONE portal or contact Jessica Breu at: jessica.breu@imux.com.
  
  
• November 19-20: Dr. Vitt and Jason Tardio, President and Chief Operating Officer of Immunic, will be hosting one-on-one meetings in London in connection with the Jefferies Global Healthcare Conference - London. To schedule a meeting, please contact Jessica Breu at: jessica.breu@imux.com.

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in industry and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company's subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com

US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-industry-and-investor-conferences-in-november-302593730.html

SOURCE Immunic, Inc.

FAQ

When will Immunic (IMUX) attend BIO-Europe in 2025?

Immunic will attend BIO-Europe in Vienna on Nov 3–5, 2025 and participate in partnering activities.

Who from Immunic will be available for meetings at BIO-Europe 2025?

Daniel Vitt, Ph.D., Hella Kohlhof, Ph.D., and Jessica Breu will participate in partnering activities at BIO-Europe.

How can investors schedule a meeting with Immunic (IMUX) at BIO-Europe?

Use the BIO-Europe partneringONE portal or contact Jessica Breu at jessica.breu@imux.com to schedule a meeting.

When and where will Immunic host one-on-one meetings related to the Jefferies Global Healthcare Conference?

Immunic will host one-on-one meetings in London on Nov 19–20, 2025 in connection with the Jefferies Global Healthcare Conference—London.

Which Immunic executives will attend the Jefferies Global Healthcare Conference meetings in London?

Daniel Vitt, Ph.D., and Jason Tardio, President and COO, will be hosting one-on-one meetings in London on Nov 19–20, 2025.

Who should I contact to arrange a meeting with Immunic (IMUX) at the Jefferies conference?

Contact Jessica Breu at jessica.breu@imux.com to schedule one-on-one meetings in London.